20Nov 2022
Health‐Related Quality of Life Outcomes in PARAGON‐HF

Health‐Related Quality of Life Outcomes in PARAGON‐HF

Heart failure (HF) is associated with poor health‐related quality of life (HRQL). Patients with HF with preserved ejection fraction (HFpEF) have similar HRQL impairment as those with reduced ejection fraction. This study describes the impact of sacubitril/valsartan on HRQL in patients with HFpEF enrolled in the PARAGON‐HF trial. Compared with valsartan, sacubitril/valsartan has a marginal benefit on KCCQ‐CSS at 8 months in patients with HFpEF. This benefit became more significant when data from all visits up to 36 months were included. This modest overall benefit was also supported by greater odds of patients reporting a clinically meaningful improvement in HRQL with sacubitril/valsartan.

  • #cardiology

Like

Save

Share